Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma
Ana Patiño‐García(Navarre Institute of Health Research), José Luis Perez‐Gracia(Clinica Universidad de Navarra), Luis M. Montuenga(Clinica Universidad de Navarra), Maria Pilar Andueza(Clinica Universidad de Navarra), Guillermo Pita(Spanish National Cancer Research Centre), Miguel F. Sanmamed(Clinica Universidad de Navarra), María J. Pajares(Universidad Pública de Navarra (UPNA)), María D. Lozano(Navarre Institute of Health Research), Ignacio Melero(University of Oxford), Anna González‐Neira(Spanish National Cancer Research Centre), Alfonso Gúrpide(Clinica Universidad de Navarra), Elizabeth Guruceaga(Universidad de Navarra), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Rubén Pı́o(National Institutes of Health), Javier J. Zulueta(Mount Sinai Hospital), Álvaro González(Memorial Sloan Kettering Cancer Center), Guillermo Serrano(Universidad de Navarra), Víctor Segura(Universidad de Navarra), Carlos de Andrea(Navarre Institute of Health Research), Marimar Ocón(Navarre Institute of Health Research), Juan P. Fusco, María Ruiz(Navarre Institute of Health Research), Ibón Tamayo
Cited by 5
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2012|1.3k
Cytokines in clinical cancer immunotherapy
|British Journal of Cancer|2018|1.2k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k